Neuroendocrine Carcinoma clinical trials at UCSF
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.
San Francisco, California and other locations
Our lead scientists for Neuroendocrine Carcinoma research studies include Adil Daud.